CTIX News Alert Cellceutix Corp (CTIX) 3.6100 01/25/2015 00:
Post# of 273387
Posted On: 01/25/2015 1:00:28 AM
Cellceutix Corp (CTIX) 3.6100 $CTIX
Cellceutix: A December To Remember May Turn Into A 2015 To Forget For CTIX
Bleecker Street Research - at Seeking Alpha - Fri Jan 23, 9:30AM CST
Autism Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 6:36AM CST
The report "Autism - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Autism. Autism is known as a multifarious developmental disability. Autism disorder is characterized by social activities, non-verbal communication and repetitive behavior. Autism is highly transmissible but the cause includes both environmental factors and genetic susceptibility. It has long been assumed that there is a common cause at the genetic, cognitive and neural levels for autism's characteristic triad of symptoms. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/autism-pipel...eport.html .
TEVA: 59.88 (+1.39), ITCI: 19.86 (-0.07), BCLI: 3.80 (-0.03), OMER: 22.86 (-0.11), NVS: 96.87 (+0.03)
Will Cannabis Be The Biggest Thing In Biotech For 2015?
ACCESSWIRE - Thu Jan 22, 8:13AM CST
CORAL GABLES, FL / ACCESSWIRE / January 22, 2015 / Attention on marijuana stocks has increased since Colorado legalized it for recreational use in 2014. With larger institutional investment flowing into the industry, there's no doubt that this may be just the beginning for stocks in this sector. With 2016 slated as the next vote for more states to come online for legalization of medical and recreational licensing, much speculation has given rise to where to invest as it would appear not many new developments may come about until more states can come online. Biotech has been one of the identified target markets as regulation does not limit these organizations to particular state laws but more on the Federal side, specifically the FDA. From prescription sprays to cannabinoid oils, the biotech space may offer potential investment opportunity prior to the next vote.
Cellceutix Phase 2b Clinical Trial of Brilacidin Accepted for Oral Presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Marketwired - Thu Jan 22, 6:00AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to report that results of its recently completed phase 2b clinical trial "A Randomized, Double-Blind Study Comparing Single-Dose and Short-Course Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin & Skin Structure Infections (ABSSSI)" will be given in an oral presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held in Copenhagen, Denmark from April 25-28, 2015. ECCMID is one of the largest annual gatherings of infectious disease experts in the world, and an ideal forum to present the results of a clinical trial. Dr. Daniel Jorgensen, Cellceutix's Chief Medical Officer, will give the presentation during a session entitled "New Antibacterial Agents - Phase 2 and Phase 3 Clinical Trials."
Cellceutix up on report of positive results in clinical trial
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 12:11PM CST
Cellceutix Reports Spleen Lesion 'Disappears' in Patient With Metastatic Stage 4 Ovarian Cancer in Clinical Trial of Anti-Cancer Drug Kevetrin
Marketwired - Tue Jan 20, 6:01AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to report the near complete disappearance of a metastatic lesion in the spleen of a Stage 4 ovarian cancer patient who was enrolled in the Company's Phase 1 clinical trial of anti-cancer drug candidate Kevetrin(TM) being conducted at Harvard Cancer Center's Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. According to information supplied by the hospital, the patient, who successfully completed three Kevetrin 3-dose cycles before discontinuing the trial, experienced increased energy, while scans showed a reduction in the amount of peritoneal fluid (ascites) during treatment with Kevetrin. Subsequent to the second and third Kevetrin cycles, scans showed the spleen lesion to be essentially undetectable and the patient's disease to be clinically stable.
Cellceutix Invites All to Attend Company's Live Webcast of Presentation at Biotech Showcase 2015 Today at 2:00 PM PT (5:00 PM ET)
Marketwired - Mon Jan 12, 6:01AM CST
Cellceutix Corporation (OTCBB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, invites all interested parties to join the Company during its live webcast presentation at Biotech Showcase 2015 today, Monday, January 12 at 2:00 PM PT (5:00 PM ET). The conference is being held at Parc 55 Wyndham San Francisco (Union Square) in San Francisco, CA on January 12-14, 2015. Cellceutix will be presenting in Room Powell.
Cellceutix Overvalued By 90-99%
Ben Sharvy - at Seeking Alpha - Fri Jan 02, 4:21PM CST
VNDA: 12.23 (+0.32), VTAE: 14.94 (+2.95), XNCR: 17.41 (+0.41)
OTC Daily Alert Stock Watch - Cellceutix (OTC: CTIX)
WorldStockWire - Mon Dec 29, 3:15PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
New medical chief at Cellceutix
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 6:28AM CST
Cellceutix Adds Dr. Daniel Jorgensen as Chief Medical Officer
Marketwired - Mon Dec 29, 6:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to announce that Daniel Jorgenson MD, MPH, MBA will join the Cellceutix team as Chief Medical Officer as of January 1, 2015.
CorMedix Update: Setting A New Standard For Catheter Care
Mark Kroenke - Seeking Alpha - Sun Dec 28, 6:07AM CST
Back in August, CorMedix (NYSEMKT: CRMD ) had a long to do list. In the last 4 months, the company has delivered on many promises: An IND for the pivotal Neutrolin study in the US was filed and accepted. The EU Neutrolin label was successfully...
CRMD: 2.24 (unch)
Cellceutix Reports Positive Results of Brilacidin in Microbiological Intent-to-Treat Population in Phase 2b ABSSSI Trial; Additional Pharmacokinetic Information to Be Submitted
Marketwired - Mon Dec 22, 6:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to provide additional information from the Company's recently completed Phase 2b clinical trial of Brilacidin for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI), as well as information on other pipeline developments.
Autism - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt9w3w/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Autism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Sumitomo Dainippon Pharma - Egenix - Novartis - Merz Pharma GmbH & Co - Mitsubishi Tanabe Pharma Corporation - Teva Pharmaceutical Industries - BrainStorm Cell Therapeutics - Avanir Pharmaceuticals - Curemark - Coronado Biosciences - Omeros Corporation - Intra-Cellular Therapies - Cellceutix Corporation - Heptares Therapeutics - Edison Pharmaceuticals - Otsuka Holdings - Reviva Pharmaceuticals - Naurex - Mnemosyne Pharmaceuticals - BioCrea - Saniona - Confluence Pharmaceuticals - MedDay For more information visit http://www.researchandmarkets.com/research/rt...m_pipeline
CNDO: 2.37 (-0.03), TEVA: 59.88 (+1.39), ITCI: 19.86 (-0.07), BCLI: 3.80 (-0.03), OMER: 22.86 (-0.11), NVS: 96.87 (+0.03)
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.65 (+0.02), PFNX: 6.74 (+0.09), INO: 8.61 (+0.11), CMRX: 38.26 (-0.63), RPTP: 9.29 (-0.17), IBIO: 0.51 (-0.01), ANAC: 34.15 (+0.82), PFE: 32.45 (-0.36), GNCA: 6.55 (-0.06), GSK: 45.01 (+0.05), AZN: 70.69 (+0.06), NVS: 96.87 (+0.03)
Otitis Media - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/2cm2ck/otitis_media) has announced the addition of the "Otitis Media - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Otitis Media, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Otitis Media and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Otitis Media - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Otitis Media pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Alcon, Inc. - GlaxoSmithKline plc - Yuhan Corporation - Arbor Pharmaceuticals, Inc. - MerLion Pharmaceuticals Pte Ltd - Otonomy, Inc. - Cellceutix Corporation - Serum Institute of India Limited - BCO Pharma Ltd For more information visit http://www.researchandmarkets.com/research/2c...itis_media
GSK: 45.01 (+0.05), OTIC: 32.93 (+3.59)
Cellceutix: Prurisol(TM) for Psoriasis -- FDA Agrees That Phase 2 Study May Begin
Marketwired - Wed Dec 10, 6:40AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the US Food and Drug Administration (FDA) has agreed that Cellceutix may begin a Phase 2 study of Prurisol (abacavir acetate), a potential chronic oral therapy for the treatment of placque psoriasis. Cellceutix conducted a Phase 1 study which demonstrated that the bioavailability of the active component of Prurisol (abacavir) was the same or lower than that of the marketed drug Ziagen(R) (abacavir sulfate). FDA noted at the end-of-Phase 1 meeting on December 8, 2014 that, pending the full review of the Phase 1 data, long-term safety data for Prurisol in the treatment of psoriasis would not be required.
Candidiasis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 5:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/9jx8b8/candidiasis) has announced the addition of the "Candidiasis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Candidiasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aureogen Biosciences, Inc. - Basilea Pharmaceutica AG - Biomar Microbial Technologies - Cellceutix Corporation - Eisai Co., Ltd. - Merck & Co., Inc. - NovaDigm Therapeutics, Inc. - Novabiotics Ltd - Novartis AG - Pacgen Life Science Corporation - Panacela Labs, Inc. - Sealife PHARMA GMBH - Sequella, Inc. - iCo Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/9j...andidiasis
MRK: 62.49 (-0.10), PBS.VN: 0.020 (-0.015), NVS: 96.87 (+0.03)
Cellceutix jumps on QIDP tag
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 12:23PM CST
CBST: 101.94 (+0.14)
Cellceutix Antibiotic Brilacidin Receives QIDP Designation From FDA
Marketwired - Mon Dec 08, 6:01AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation for Brilacidin as a new treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) ahead of its meeting this month with Cellceutix regarding Cellceutix's planned Phase 3 trial of Brilacidin for ABSSSI. Brilacidin, the Company's lead drug in a new class of antibiotics called defensin-mimetics, completed a Phase 2b trial in September showing, amongst other things, a single dose of Brilacidin to be as effective in treatment of ABSSSI as a FDA-approved seven-day dosing regimen of daptomycin.
Cellceutix: A December To Remember May Turn Into A 2015 To Forget For CTIX
Bleecker Street Research - at Seeking Alpha - Fri Jan 23, 9:30AM CST
Autism Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 6:36AM CST
The report "Autism - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Autism. Autism is known as a multifarious developmental disability. Autism disorder is characterized by social activities, non-verbal communication and repetitive behavior. Autism is highly transmissible but the cause includes both environmental factors and genetic susceptibility. It has long been assumed that there is a common cause at the genetic, cognitive and neural levels for autism's characteristic triad of symptoms. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/autism-pipel...eport.html .
TEVA: 59.88 (+1.39), ITCI: 19.86 (-0.07), BCLI: 3.80 (-0.03), OMER: 22.86 (-0.11), NVS: 96.87 (+0.03)
Will Cannabis Be The Biggest Thing In Biotech For 2015?
ACCESSWIRE - Thu Jan 22, 8:13AM CST
CORAL GABLES, FL / ACCESSWIRE / January 22, 2015 / Attention on marijuana stocks has increased since Colorado legalized it for recreational use in 2014. With larger institutional investment flowing into the industry, there's no doubt that this may be just the beginning for stocks in this sector. With 2016 slated as the next vote for more states to come online for legalization of medical and recreational licensing, much speculation has given rise to where to invest as it would appear not many new developments may come about until more states can come online. Biotech has been one of the identified target markets as regulation does not limit these organizations to particular state laws but more on the Federal side, specifically the FDA. From prescription sprays to cannabinoid oils, the biotech space may offer potential investment opportunity prior to the next vote.
Cellceutix Phase 2b Clinical Trial of Brilacidin Accepted for Oral Presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Marketwired - Thu Jan 22, 6:00AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to report that results of its recently completed phase 2b clinical trial "A Randomized, Double-Blind Study Comparing Single-Dose and Short-Course Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin & Skin Structure Infections (ABSSSI)" will be given in an oral presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held in Copenhagen, Denmark from April 25-28, 2015. ECCMID is one of the largest annual gatherings of infectious disease experts in the world, and an ideal forum to present the results of a clinical trial. Dr. Daniel Jorgensen, Cellceutix's Chief Medical Officer, will give the presentation during a session entitled "New Antibacterial Agents - Phase 2 and Phase 3 Clinical Trials." Cellceutix up on report of positive results in clinical trial
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 12:11PM CST
Cellceutix Reports Spleen Lesion 'Disappears' in Patient With Metastatic Stage 4 Ovarian Cancer in Clinical Trial of Anti-Cancer Drug Kevetrin
Marketwired - Tue Jan 20, 6:01AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to report the near complete disappearance of a metastatic lesion in the spleen of a Stage 4 ovarian cancer patient who was enrolled in the Company's Phase 1 clinical trial of anti-cancer drug candidate Kevetrin(TM) being conducted at Harvard Cancer Center's Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. According to information supplied by the hospital, the patient, who successfully completed three Kevetrin 3-dose cycles before discontinuing the trial, experienced increased energy, while scans showed a reduction in the amount of peritoneal fluid (ascites) during treatment with Kevetrin. Subsequent to the second and third Kevetrin cycles, scans showed the spleen lesion to be essentially undetectable and the patient's disease to be clinically stable. Cellceutix Invites All to Attend Company's Live Webcast of Presentation at Biotech Showcase 2015 Today at 2:00 PM PT (5:00 PM ET)
Marketwired - Mon Jan 12, 6:01AM CST
Cellceutix Corporation (OTCBB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, invites all interested parties to join the Company during its live webcast presentation at Biotech Showcase 2015 today, Monday, January 12 at 2:00 PM PT (5:00 PM ET). The conference is being held at Parc 55 Wyndham San Francisco (Union Square) in San Francisco, CA on January 12-14, 2015. Cellceutix will be presenting in Room Powell. Cellceutix Overvalued By 90-99%
Ben Sharvy - at Seeking Alpha - Fri Jan 02, 4:21PM CST
VNDA: 12.23 (+0.32), VTAE: 14.94 (+2.95), XNCR: 17.41 (+0.41)
OTC Daily Alert Stock Watch - Cellceutix (OTC: CTIX)
WorldStockWire - Mon Dec 29, 3:15PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
New medical chief at Cellceutix
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 6:28AM CST
Cellceutix Adds Dr. Daniel Jorgensen as Chief Medical Officer
Marketwired - Mon Dec 29, 6:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to announce that Daniel Jorgenson MD, MPH, MBA will join the Cellceutix team as Chief Medical Officer as of January 1, 2015. CorMedix Update: Setting A New Standard For Catheter Care
Mark Kroenke - Seeking Alpha - Sun Dec 28, 6:07AM CST
Back in August, CorMedix (NYSEMKT: CRMD ) had a long to do list. In the last 4 months, the company has delivered on many promises: An IND for the pivotal Neutrolin study in the US was filed and accepted. The EU Neutrolin label was successfully...
CRMD: 2.24 (unch)
Cellceutix Reports Positive Results of Brilacidin in Microbiological Intent-to-Treat Population in Phase 2b ABSSSI Trial; Additional Pharmacokinetic Information to Be Submitted
Marketwired - Mon Dec 22, 6:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to provide additional information from the Company's recently completed Phase 2b clinical trial of Brilacidin for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI), as well as information on other pipeline developments. Autism - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt9w3w/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Autism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Sumitomo Dainippon Pharma - Egenix - Novartis - Merz Pharma GmbH & Co - Mitsubishi Tanabe Pharma Corporation - Teva Pharmaceutical Industries - BrainStorm Cell Therapeutics - Avanir Pharmaceuticals - Curemark - Coronado Biosciences - Omeros Corporation - Intra-Cellular Therapies - Cellceutix Corporation - Heptares Therapeutics - Edison Pharmaceuticals - Otsuka Holdings - Reviva Pharmaceuticals - Naurex - Mnemosyne Pharmaceuticals - BioCrea - Saniona - Confluence Pharmaceuticals - MedDay For more information visit http://www.researchandmarkets.com/research/rt...m_pipeline
CNDO: 2.37 (-0.03), TEVA: 59.88 (+1.39), ITCI: 19.86 (-0.07), BCLI: 3.80 (-0.03), OMER: 22.86 (-0.11), NVS: 96.87 (+0.03)
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.65 (+0.02), PFNX: 6.74 (+0.09), INO: 8.61 (+0.11), CMRX: 38.26 (-0.63), RPTP: 9.29 (-0.17), IBIO: 0.51 (-0.01), ANAC: 34.15 (+0.82), PFE: 32.45 (-0.36), GNCA: 6.55 (-0.06), GSK: 45.01 (+0.05), AZN: 70.69 (+0.06), NVS: 96.87 (+0.03)
Otitis Media - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/2cm2ck/otitis_media) has announced the addition of the "Otitis Media - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Otitis Media, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Otitis Media and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Otitis Media - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Otitis Media pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Alcon, Inc. - GlaxoSmithKline plc - Yuhan Corporation - Arbor Pharmaceuticals, Inc. - MerLion Pharmaceuticals Pte Ltd - Otonomy, Inc. - Cellceutix Corporation - Serum Institute of India Limited - BCO Pharma Ltd For more information visit http://www.researchandmarkets.com/research/2c...itis_media
GSK: 45.01 (+0.05), OTIC: 32.93 (+3.59)
Cellceutix: Prurisol(TM) for Psoriasis -- FDA Agrees That Phase 2 Study May Begin
Marketwired - Wed Dec 10, 6:40AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the US Food and Drug Administration (FDA) has agreed that Cellceutix may begin a Phase 2 study of Prurisol (abacavir acetate), a potential chronic oral therapy for the treatment of placque psoriasis. Cellceutix conducted a Phase 1 study which demonstrated that the bioavailability of the active component of Prurisol (abacavir) was the same or lower than that of the marketed drug Ziagen(R) (abacavir sulfate). FDA noted at the end-of-Phase 1 meeting on December 8, 2014 that, pending the full review of the Phase 1 data, long-term safety data for Prurisol in the treatment of psoriasis would not be required. Candidiasis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 5:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/9jx8b8/candidiasis) has announced the addition of the "Candidiasis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Candidiasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aureogen Biosciences, Inc. - Basilea Pharmaceutica AG - Biomar Microbial Technologies - Cellceutix Corporation - Eisai Co., Ltd. - Merck & Co., Inc. - NovaDigm Therapeutics, Inc. - Novabiotics Ltd - Novartis AG - Pacgen Life Science Corporation - Panacela Labs, Inc. - Sealife PHARMA GMBH - Sequella, Inc. - iCo Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/9j...andidiasis
MRK: 62.49 (-0.10), PBS.VN: 0.020 (-0.015), NVS: 96.87 (+0.03)
Cellceutix jumps on QIDP tag
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 12:23PM CST
CBST: 101.94 (+0.14)
Cellceutix Antibiotic Brilacidin Receives QIDP Designation From FDA
Marketwired - Mon Dec 08, 6:01AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation for Brilacidin as a new treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) ahead of its meeting this month with Cellceutix regarding Cellceutix's planned Phase 3 trial of Brilacidin for ABSSSI. Brilacidin, the Company's lead drug in a new class of antibiotics called defensin-mimetics, completed a Phase 2b trial in September showing, amongst other things, a single dose of Brilacidin to be as effective in treatment of ABSSSI as a FDA-approved seven-day dosing regimen of daptomycin. 
(0)
(0)